REMS programs, a plain-language explainer
What a Risk Evaluation and Mitigation Strategy actually requires, beyond the label itself.
Most drugs are considered safe enough to prescribe based on their label alone, the approved indication, dosing, and standard safety information. A REMS program exists for the smaller set of drugs where the FDA has decided the label isn't sufficient on its own, and additional structure is needed to manage a specific serious risk.
What it is
REMS stands for Risk Evaluation and Mitigation Strategy. It's a set of requirements the FDA can attach to a drug's approval, beyond standard labeling, specifically to manage a known serious risk. A REMS isn't a single fixed template. What it requires varies by drug and by the risk it's addressing, but it typically layers additional obligations onto prescribing, dispensing, or patient monitoring that go beyond what the label alone would require.
Why it matters
A REMS changes what "on-label" actually means in practice for that specific product. A claim or a use can be technically within the approved indication and still be handled incorrectly if it doesn't account for the REMS requirements layered on top of that indication. For promotional content, this means understanding a product's REMS obligations is part of understanding what can be said and shown, not a separate concern handled entirely outside of marketing.
This is also why REMS drugs often carry more restrictive promotional practices than the label's safety section alone would suggest. The REMS exists because the FDA judged the underlying risk serious enough to require structural safeguards, and promotional content needs to be consistent with those safeguards, not just with the general safety information.
How it actually works
REMS requirements commonly include one or more of the following, depending on the specific drug and risk:
- A Medication Guide or patient package insert, given directly to patients at the point of dispensing, beyond what standard labeling requires.
- A communication plan, requiring the manufacturer to proactively inform healthcare providers about specific risks and appropriate use.
- Elements to Assure Safe Use (ETASU), the most restrictive tier, which can require prescriber certification, pharmacy certification, patient monitoring, or enrollment in a registry before a patient can receive the drug.
Not every REMS includes all of these. The specific combination is decided based on the risk being managed and how serious the FDA considers it relative to the drug's benefit.
Common misunderstandings
A common assumption is that a REMS is roughly equivalent to a Boxed Warning, since both signal a serious risk. They address different things. A Boxed Warning is a labeling requirement, information on the label itself. A REMS is a program, a set of operational requirements around how the drug is prescribed, dispensed, or monitored, which can exist alongside a Boxed Warning or independently of one.